Slide 1: 2Q FY2026 Financial Results Overview
2Q FY2026 FINANCIAL RESULTS OVERVIEW May 27, 2026
Slide 2: Safe Harbor
Thank You for Your Attention Safe Harbor This presentation contains forward- successfully adapt its cost structures to The company assumes no obligation to looking statements (including, without continuing changes in business update the information in these limitation, information, and future condit
Slide 3: Agilent 2Q26 Results
Agilent 2Q26 Results 6.3% revenue growth(1)(2) beats high-end of guidance by 80 bps Operating Margins also above guide by 80 bps $ • Revenue of $1.83B, led by strong high-single-digit Revenue Operating Margin EPS $1.83B 26.4% $1.49 (2) (2) instrument growth • Operating margin 26.4%(2), a 130 bps inc
Slide 4: Q2 results by business group
Q2 results LDG +9% • Replacement cycle momentum with low double-digit LC & LC/MS growth Core Growth(1)(2) • Omnis family, CDx services drive 22.0% demonstrate Operating Margin(2) +12% Reported double-digit Cancer Dx growth compounding value of the AMG +11% • Market-leading Spectroscopy tools Ignite
Slide 5: Americas and Europe deliver strong broad-based growth; APAC impacted by tough China compares
GEOGRAPHY PRODUCT TYPE Core Revenue Growth by Geography Americas and Europe Americas 42% of Agilent Revenue(2) deliver strong broad- 8% -1% (1) (1) based growth; APAC 11% Europe (1) 28% of Agilent Revenue(2) impacted by tough Asia-Pacific (APAC) China compares y/y 30% of Agilent Revenue(2) (1) Core
Slide 6: Q2 revenue mix
GEOGRAPHY PRODUCT TYPE % of total revenue Q2 revenue mix 66% Consumables Services Robust growth in instruments, Informatics increasing recurring revenue 34% mix Instruments 06
Slide 7: Momentum in our largest end markets
Q2 Core Share Growth(1) of Agilent Results Revenue(2) +6% 36% Fifth quarter of mid-single to low-double-digit growth, Pharma including low double-digit growth in biotech Q2 REVENUE Diagnostics & +11% 16% Strength driven by our expanding Cancer Diagnostics Momentum in Clinical offerings, including Om
Slide 8: FY26 Guidance
FY26 Guidance Net (1) Revenue ($) $7.39B $7.49B +$40M at the midpoint vs. prior guide Increasing core revenue Core Revenue +4.5% +6.0% +1.8% FX growth(2), margin expansion, Growth(2) +30 bps at the midpoint vs. prior guide and EPS outlook Operating Margins +85 bps YoY Updated outlook reflects +10 bp
Slide 9: 3Q26 Guidance
3Q26 Guidance (1) Net Revenue ($B) $1.83B $1.85B Expect strong H1 Core Revenue momentum to continue Growth(2) +4.4% +5.9% +0.6% FX Reflects continued healthy demand trends EPS $1.48 $1.50 $8M Net Interest + Other Inc/(Exp) 283M Share Count Q3 Q3 (1) Based on forecasted currency exchange rates. Prese
Slide 10: Continued Growth Momentum
Continued Growth Momentum Updated outlook reflects accelerating 2-year stack growth across FY26 11.2% 12.5% 11.1%(3) 6.0%(3) (1)(2) (1) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX. (2) Presented on a non-GAAP basis; re
Slide 11: Get in touch with us
Get in touch with us Trusted Answers investor_relations@agilent.com www.investor.agilent.com